source
- STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricingThe pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.STAT · 3mo ago↗ source
- STAT+: A new attack on AMA’s billing codesA key GOP lawmaker is broadening the party's efforts to combat health care fraud.STAT · 3mo ago↗ source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 3mo ago↗ source